Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether NORADRENERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether switch to another antipsychotic changes acceptability of the treatment: leaving the study early compared with antipsychotic cessation (very low certainty).
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether specific antipsychotic changes acceptability of the treatment: leaving the study early compared with other drugs (very low certainty).
1 finding from 1 review
Leaving the study early · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether reduced dose of antipsychotics changes acceptability of the treatment: leaving the study early compared with antipsychotic maintenance (very low certainty).
1 finding from 1 review
RR 0.33 [0.06, 1.99]
1 study · 8 participants
Very low
Secondary outcome: acceptability of treatment · people with Alzheimer's disease
Donepezil 23 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with donepezil 10 mg/day (moderate certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with donepezil 5 mg/day (moderate certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · people with severe Alzheimer's disease
Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with placebo (moderate certainty).
1 finding from 1 review
Acceptability · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Acceptability of treatment (17 weeks) · women with a history of postnatal depression
1 finding from 1 review
Intervention not reported
Acceptability of treatment (17 weeks) · women with a history of postnatal depression
1 finding from 1 review
Acceptability
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
acceptability and safety of treadmill training ‐ No intervention control group (co‐interventions were not similar in both groups) Number of adverse events and drop‐outs · people with stroke
1 finding from 1 review
Acceptability ‐ total dropouts · people with co‐occurring depression and alcohol dependence
Antidepressants showed no clear difference in acceptability: dropouts compared with placebo: all studies (low certainty).
1 finding from 1 review
Treatment acceptability: dropouts from treatment · children and adolescents, 11 to 18 years old, with mental health problems
It is very uncertain whether client feedback changes treatment acceptability: dropouts from treatment compared with no client feedback (very low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · non response in schizophrenia
Antipsychotic dose increase showed no clear difference in leaving the study early: acceptability ‐ leaving early due to any… compared with antipsychotic dose continuation (low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · non response in schizophrenia
1 finding from 1 review
Secondary outcome: acceptability of treatment · children and adolescents, aged 10 to 18 years, with long‐term physical conditions
1 finding from 1 review
Physical fitness: peak exercise oxygen uptake (mL/kg/minute) · people with Child‐Pugh stage A or B cirrhosis
1 finding from 1 review
Leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + AMISULPIRIDE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + QUETIAPINE (Genc 2007) (very low certainty).
1 finding from 1 review